西罗莫司
医学
肝细胞癌
肝移植
PI3K/AKT/mTOR通路
雷帕霉素的作用靶点
移植
内科学
免疫抑制
细胞凋亡
生物
生物化学
作者
Guanghan Fan,Chen-Zhi Zhang,Fengqiang Gao,Xuyong Wei,Sunbin Ling,Kai Wang,Jianguo Wang,Shusen Zheng,Mehrdad Nikfarjam,Xiao Xu
标识
DOI:10.1016/j.hbpd.2022.10.004
摘要
Liver transplantation (LT) is an effective treatment option for end-stage liver disease. Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin, are widely used post LT.In this review, we focused on the anti-cancer activities and metabolic side effects of rapamycin after LT. The literature available on PubMed for the period of January 1999-September 2022 was reviewed. The key words were rapamycin, sirolimus, liver transplantation, hepatocellular carcinoma, diabetes, and lipid metabolism disorder.Rapamycin has shown excellent effects and is safer than other immunosuppressive regimens. It has exhibited excellent anti-cancer activity and has the potential in preventing hepatocellular carcinoma (HCC) recurrence post LT. Rapamycin is closely related to two long-term complications after LT, diabetes and lipid metabolism disorders.Rapamycin prevents HCC recurrence post LT in some patients, but it also induces metabolic disorders. Reasonable use of rapamycin benefits the liver recipients.
科研通智能强力驱动
Strongly Powered by AbleSci AI